THE STUFF THAT human health care LEADERS ARE MADE OF

Tatsuyuki Yasuno is responsible for the strategic direction of the Americas Region. He has full operating responsibility for the U.S. business, and provides regional management support and oversight to all of Eisai's operating companies and units in the Americas. He has served as a corporate officer of Eisai Co., Ltd., the parent company of Eisai Inc., since 2016, and is the president of the Eisai USA Foundation, the company's philanthropic arm.

Since joining Eisai in 1991, Tatsuyuki has held a number of key executive roles in Japan, Europe and the United States. Most recently, he served as vice president of Global Partnership Development at Eisai Co., Ltd. In this position, which he began in March 2018, he led the team responsible for executing the company's global strategic oncology collaboration with Merck (known as MSD outside the United States and Canada).

Tatsuyuki received his Master of Business Administration (MBA) from the Kellogg School of Management at Northwestern University. He earned his Bachelor of Political Science degree from Waseda University in Tokyo, Japan.

Ivan Cheung concurrently serves as Chairman of Eisai Inc. in the United States and Global President of Eisai’s Neurology Business Group. In the latter role, he is responsible for Eisai’s global end-to-end activities from discovery research and clinical development to brand commercialization and business development across Alzheimer’s disease & dementia, epilepsy, sleep-wake rhythm and neurodegenerative diseases. He is also a Senior Corporate Officer for Eisai Co., Ltd.

Since joining Eisai in 2005, Ivan has held positions of rising responsibility across corporate planning & strategy, corporate finance, talent management, global R&D, the U.S. commercial business, the Japan consumer health care business, the global oncology business and the global neurology business. Prior to Eisai, he was a member of the Global Health Practice at Booz Allen Hamilton, where he provided strategy and operations consulting to biopharmaceutical and health care clients in the U.S., Europe and Asia.

Ivan received his MBA from Harvard Business School, and earned a Bachelor of Science degree in Civil/Environmental Engineering with a double major in Economics from Duke University. He is a Board member of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), as well as the Board chairman of KAN Research Institute in Kobe, Japan.

Dr. Kramer oversees the product creation cycle — including clinical introduction and regulatory approval — of innovative projects in the global neuroscience and general medicine area.

He has been a senior executive at Eisai since 2007, beginning as Executive Vice President of Global Clinical Research before being promoted to multiple roles of increasing responsibility, including Chief Operating Officer of Eisai Medical Research, President of Neurology Product Creation Unit, and Chief Medical Officer of the company’s Neurology Business Group. During his tenure at Eisai, he has supervised and contributed to the development of a number of compounds that have received FDA approval.

Prior to joining Eisai, Dr. Kramer oversaw clinical development, pharmacovigilance, drug safety and medical affairs for PAR Pharmaceutical, Inc. Earlier in his career, he held clinical research positions in a variety of therapeutic areas at Novartis, the R.W. Johnson Pharmaceutical Research Institute and Carter-Wallace, Inc.

Dr. Kramer is a Fellow of the American Board of Psychiatry and Neurology (1987) and the Philadelphia College of Physicians (1987). He received his M.D. from Hahnemann Medical College. He completed his internship in internal medicine at the University of California at Irvine, and his residency in neurology at the University of Virginia. Dr. Kramer earned his Bachelor of Arts degree from Lycoming College.

Dr. Owa is responsible for all discovery research and oversight of clinical development for the company’s oncology business.

Since joining Eisai as a scientist in the Cancer Research Division in 1991, Dr. Owa has assumed positions of increasing responsibility within the R&D operations. He specializes in anticancer research, including drug discovery and the development of sulfonamide anticancer agents, as well as target and biomarker identification of novel anticancer small molecules.

Dr. Owa received his Ph.D. in Organic Chemistry, Medicinal Chemistry and Cancer Chemistry from the University of Tokyo, with a focus on chemistry and biology of naturally-occurring and manmade bleomycins. In addition, he completed a two-year, post-doctoral fellowship in the Department of Chemistry and Chemical Biology at Harvard University.

Alexander Scott oversees all the functional departments of the company’s regional corporate services operations, including Advocacy, Compliance, Corporate Communications, Legal, Finance, Human Resources, Internal Audit, Information Technology and Product Safety. Alex is a Corporate Officer for Eisai Co., Ltd. He also serves as a trustee of the Eisai USA Foundation, the company’s philanthropic arm and as a member of the America's Executive Committee.

Since joining Eisai in 1992, Alex has helped craft the company’s U.S. globalization strategy and establish a commercial infrastructure through a variety of roles in Commercial Planning, Corporate Strategy, Business Development and Alliance Management. He has negotiated global alliances with a number of companies and played a key role in establishing business collaborations with more than 25 pharmaceutical companies. He also managed Eisai’s acquisitions of MGI PHARMA, INC. and Morphotek, Inc.

Alex holds a Bachelor of Arts in Government from Wesleyan University and a Master of Business Administration degree from Duke University. He is a member of the Licensing Executives Society, and serves as Treasurer and a Board Member of Gilda’s Club New York City.

With close to 30 years of experience in the pharmaceutical industry, Paul Hawthorne leads the Commercial, Medical Affairs and Market Access organizations for Eisai U.S. and Canada Oncology and Neurology portfolios. Paul and his teams are responsible for the development and implementation of our commercialization, data generation, data dissemination and access strategies that enable Eisai to fulfill its PURPOSE, our human health care (hhc) mission. Paul also serves as a member of the Americas Executive Committee.

In April 2016, Paul joined Eisai with the initial goal of creating and driving commercial strategies for the company’s Neurology portfolio, before being promoted to Chief Commercial Officer in January 2019 and then to his current role in December 2019.

Prior to Eisai, he spent 25 years with Sanofi, where he held senior leadership positions of increasing responsibility across all therapeutic areas.

Paul holds a Master of Business Administration in Marketing from LaSalle University. He earned his undergraduate degree from the University of Pittsburgh.

Yasutaka Yoshida is responsible for evaluating, managing and executing the strategic initiatives and market opportunities that support Eisai’s short-term and long-term planning and strategies, including operational investments, capital expansions, strategic alliances and partnerships, acquisitions and divestitures.

Mr. Yoshida, who joined Eisai in 2004 as a Medical Sales Representative, has held a variety of diverse roles of increasing responsibility during his tenure with the company. Prior to being appointed to his current role in July 2020, Mr. Yoshida spent two years working in the company’s Executive Office in Japan. In June 2019, he was promoted to Senior Director of the CEO Office, a role in which he directly supported the company’s global CEO, Dr. Haruo Naito. He has relocated to the company’s U.S. headquarters in Woodcliff Lake, N.J. Before working in the Executive Office, he served two years as Associate Director of the Corporate Planning and Strategy Department, acting as the liaison between the Americas region and the global headquarters to assist in the development of the company’s strategy and financial planning. Earlier in his career, Mr. Yoshida spent four years as Manager of the Government Affairs Department, in which he worked with the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) and was a management member on Japan Pricing Policy. He also spent two years as Associate Manager in the Human Resources Department, and served two years as Associate Manager at the Japan Business Headquarters after his promotion from a Medical Sales Representative.

Mr. Yoshida holds of Bachelor of Law degree from Kobe University, and an English Language degree from the Kansai Gaidai University in Japan.

Neriman Botas serves as Executive Vice President, Human Resources. In this role, she works with Eisai's business leaders to identify priorities, align resources and cultivate a culture that enables all employees to thrive at the company. Neriman is a member of the Americas Executive Committee, as well as a trustee of the Eisai USA Foundation, the company’s philanthropic arm.

Since joining the company in 2004, Neriman has led the Human Resources organization in the design and deployment of progressive talent management practices that promote growth, accountability and empowerment. Prior to joining Eisai, Neriman spent 19 years at Schering-Plough Corporation, where she developed her human resources career in roles spanning all business segments, including both U.S. and global responsibilities.

Neriman received her Bachelor of Arts in psychology from Douglass College of Rutgers University in New Jersey. She also completed the Executive Human Resources Development Program at Cornell University School of Industrial and Labor Relations.

Patrick Coyle has full oversight and responsibility for leading Eisai's financial operations in the United States and Canada. He serves as a member of the company's Executive Committee.

Patrick is an inclusive leader with two decades of leadership experience in financial planning and analysis, accounting, operations and strategy development from his tenure at several prominent healthcare companies. During his career, he held positions of increasing responsibility where his contributions were pivotal to optimize people, processes and technology in the Finance departments at Novartis, Bayer HealthCare Pharmaceuticals, Sun Chemical and Computer Horizons Corporation. Before joining Eisai in 2019, he was Vice President, Financial Planning and Analysis at INSMED Inc, where his partnership with the business accelerated the Life Cycle Management and prioritization of pipeline investments.

He earned his MBA degree in Business Management and a Bachelor of Science degree in Business Management and Accounting from The School of Business at Montclair State University in New Jersey. Patrick completed the Finance Leadership Program at Harvard Business School in 2017.

Stephen Davies is responsible for leading the Information Technology function, including IT operations, application development, maintenance, technology infrastructure, consulting and advisory services for all of Eisai’s business units in the Americas and select global R&D functions. He is also a member of the Executive Committee for the Americas.

With more than 20 years of pharmaceutical industry IT experience, Stephen leads the development of IT and business model strategies that bring together internal stakeholders and functional support groups to rapidly connect Eisai’s business challenges and technology architecture, to provide valued services to the company’s customers and patients. Prior to joining Eisai in 2018, he held executive IT roles at Savient Pharmaceuticals, Inc., Imclone Systems and Boehringer Ingelheim. He was also the lead commercial life sciences research director at Gartner and published more than 35 research documents during his tenure at the company.

Stephen earned a Bachelor of Arts degree in Communications and a minor in Computer Science from Rowan University.

Joel Beetsch, Ph.D., serves as Vice President of Corporate Affairs at Eisai Inc. In this position, Dr. Beetsch is responsible for cultivating and maintaining Eisai's corporate reputation through strategic communications, government affairs, public policy and patient advocacy. He also serves as Vice President of the Eisai USA Foundation, Inc., the charitable arm of Eisai Inc. He is a member of the Executive Committeee for the Americas.

Embracing Eisai’s focus on innovation and its human health care (hhc) mission of giving first thought to patients and their families and helping to increase the benefits health care provides, Dr. Beetsch and his team utilize a collaborative approach to execute a patient-focused corporate strategy working alongside multiple patient, provider, payer, policy stakeholders and organizations. The team works to address and provide effective solutions to some of healthcare biggest challenges, including patient access to clinical trials and affordable medicines.

During his 20-plus year tenure in the biopharmaceutical industry, Dr. Beetsch has held several executive-level Medical and Corporate Affairs positions at Celgene, Sanofi and Merck. He began his career in the industry as a medical science liaison at Bristol-Myers Squibb.

Dr. Beetsch earned his Doctorate in Neurobiology/Biochemistry from the Boonshoft School of Medicine at Wright State University, and received further training in cell biology at the Washington University School of Medicine. He currently serves as the co-chairperson for the steering committee of the Susan G. Komen Big Data for Patients (BD4P) initiative, and is the President of the National Advisory Board for Family Reach, a non-profit organization dedicated to alleviating the financial burden of cancer.

Vincent Andrews leads Eisai's Legal Department and the Ethics & Compliance Department. Vince provides strategic executive oversight on Legal Matters, the Corporate Compliance Program and manages day-to-day Legal and Compliance operations, as well as Product Security. Over the past 16 plus years at Eisai, Vince has led or overseen several key areas for Legal‚ including Life Sciences Transactions‚ Alliance Management, Intellectual Property, and Eisai's litigation and investigations. Vince serves a member of the Americas Executive Committee, the Global Risk Management Committee and the Global Product Security Committee.

Prior to joining Eisai‚ Vince served as Assistant General Counsel to Eyetech Pharmaceuticals‚ a successful biotech start-up‚ and as Associate General Counsel to MIM Corporation in Elmsford‚ NY‚ a publicly-traded specialty pharmaceutical distributor and pharmaceutical benefit manager. In addition‚ Vince spent over five years at Schulte Roth & Zabel, advising private and public companies on corporate transactions‚ securities issuances and filings and general corporate matters.

Vince received his Juris Doctor degree from the Northeastern University School of Law. He earned his Bachelor of Arts degree in Political Science from Binghamton University.